The current standard therapies for advanced NSCLC include immune checkpoint inhibitors with combination chemotherapy or immunotherapy alone in patients with newly diagnosed KRAS-mutated NSCLC [40]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.